Search for: "Androgel Antitrust Litigation (No. II)" Results 1 - 12 of 12
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Jun 2013, 9:51 am by Sheppard Mullin
In 2006, all parties to the patent litigation reached a settlement, which provided that the generic manufacturers (i) would not bring their products to market until August 31, 2015, 65 months before Solvay’s patent expired, unless another party marketed a generic sooner; and (ii) would promote AndroGel to urologists. [read post]
3 Mar 2010, 2:26 pm
Per se illegality analysis did not apply to reverse payments, the court noted.The February 22 decision is In re: Androgel Antitrust Litigation (No. [read post]
24 Jun 2013, 10:08 am by Sheppard Mullin
In 2006, all parties to the patent litigation reached a settlement, which provided that the generic manufacturers (i) would not bring their products to market until August 31, 2015, 65 months before Solvay’s patent expired, unless another party marketed a generic sooner; and (ii) would promote AndroGel to urologists. [read post]
24 Jun 2013, 6:08 am by Bradley Graveline
In 2006, all parties to the patent litigation reached a settlement, which provided that the generic manufacturers (i) would not bring their products to market until August 31, 2015, 65 months before Solvay’s patent expired, unless another party marketed a generic sooner; and (ii) would promote AndroGel to urologists. [read post]
26 Jun 2013, 5:30 am by RatnerPrestia
Supreme Court ruled that “reverse payment” agreements in settlement of pharmaceutical patent litigation are not per se antitrust violations. [read post]
11 Oct 2009, 9:37 am
The September session produced these rulings: Transferred Litigations (.pdfs)  MDL No. 2084 -- IN RE: AndroGel Antitrust Litigation (No. [read post]
11 Oct 2012, 11:17 am by Gene Quinn
See FTC Seeks SCOTUS Review in AndroGel "Pay-for-Delay" Case. [read post]
11 Oct 2012, 11:17 am by Gene Quinn
See FTC Seeks SCOTUS Review in AndroGel "Pay-for-Delay" Case. [read post]
17 Jun 2013, 1:03 pm by David Kemp
It would be incongruous to determine antitrust legality by looking only at patent law policy, and not at antitrust policies. [read post]